THEO-24
What it isNon-selective phosphodiesterase inhibitor and adenosine antagonist; asthma and COPD.
Why this oneOral bronchodilation with a mild anti-inflammatory effect, and it is very cheap where inhalers are not available.
What limits itA narrow therapeutic index needing levels, and CYP1A2 makes it interaction-prone — ciprofloxacin and smoking cessation both push it into toxicity.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Chronic asthma / reversible bronchospasm (maintenance) | Adults & children >45 kg (16–60 yr, no risk factors) | 300 mg/day divided Q12h | After 3 days →400 mg/day; after 3 more days →600 mg/day, guided by serum level | 600 mg/day (400 mg/day if elderly/risk factors for impaired clearance) |
| Chronic asthma / reversible bronchospasm | Children <45 kg (6–15 yr) | 12–14 mg/kg/day (max 300 mg) divided Q12h | After 3 days →16 mg/kg/day (max 400 mg); after 3 more →20 mg/kg/day (max 600 mg) | 20 mg/kg/day up to 600 mg/day (16 mg/kg/day up to 400 mg/day if risk factors) |
Titration Increase dose only if previous dose tolerated, at intervals of no less than 3 days
Renal Undefined
Hepatic Undefined
Titrate to peak serum theophylline 10–20 mcg/mL; cap at 400 mg/day with risk factors for impaired clearance or in the elderly
Pregnancy Teratogenic in animals; use during pregnancy only if potential benefit justifies potential fetal risk
Lactation Undefined
NO BOXED WARNINGS
Principal riskNarrow index; CYP1A2 interactions push it into toxicity
Cost, est. cash$30–$500/month
Generic entry1982
Legacy pregnancy categoryC
Defining liabilityNarrow therapeutic index; overdose can cause refractory seizures and life-threatening tachyarrhythmias.

Open Theophylline in the interactive console ↗

